Week in Review: MicroTech Medical Staging $245 Million HK IPO for Diabetes Products
October 09, 2021 at 03:37 AM EDT
Deals and Financings Hangzhou MicroTech Medical, is conducting a $245 million Hong Kong IPO to support its diabetes monitoring and treatment products; LianBio, a Princeton , NJ-Shanghai biopharma, will conduct a $100 million IPO on NASDAQ for its pipeline of nine in-licensed candidates; AffyImmune of Massachusetts closed a $30 million Series A+ round from Hong Kong 's ORI Capital for CAR T therapies aimed at solid tumors; I-Mab is in wide-ranging discussions with US and EU biopharmas to out-license an I-Mab asset or secure a direct investment; Trials and Approvals Shanghai 's Zai Lab reported its in-licensed HER2 drug met its endpoints in patients with previously treated HER2+ breast cancer; Himalaya Therapeutics of Shanghai submitted four INDs in China for two Conditionally Active Biologics discovered by San Diego 's BioAtla; Shanghai NovoCodex Pharma reported positive interim data from a China trial of its lead drug in patients with HER2+ metastatic gastric cancer; COVID-19 Pandemic Beijing 's Brii Bio reported data from a trial of its combination mAb COVID-19 therapy that suggests the candidate may be effective in later stage disease; Kintor Pharma of Suzhou started a global Phase III trial of proxalutamide in hospitalized COVID-19 patients. Stock Symbols: (HK: 2235) (NSDQ: IMAB) (NSDQ: ZLAB; HKEX: 9688) (HK: 2137) (HK: 9939) Share this with colleagues: // //
